Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives

NCT06036719

Status	RECRUITING
Sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Enrollment	3,000 participants

Key Eligibility Criteria

Inclusion (6)

- Confirmed diagnosis of IIP established based on clinical, radiological, or functional criteria.
- Confirmed diagnosis of non-IPF progressive fibrotic interstitial lung disease (PF-ILD) with fibrosis e 10% on CT scan, disease worsening not related to pulmonary embolism, decompensated heart failure, or lower respiratory tract infection, and disease progression despite "appropriate management" evaluated over a period of up to 24 months:
- A relative decline in Forced Vital Capacity (FVC) of at least 10% from predicted value, with or without clinical deterioration, or
- A combination of at least 2 of the following criteria: a relative decline in FVC between 5% and 10% from predicted value, worsening respiratory symptoms, increased extent of pulmonary fibrosis on thoracic CT scan.
- Confirmed diagnosis of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) (American College of Rheumatology criteria), with a total score e 9 and disease extent involving e 10% of the lungs (defined by reticular abnormalities, honeycombing, and ground-glass opacities) on high-resolution CT (HRCT) scan.

... and 1 more (see full listing online)

Locations (1 total)

RaDiCo-ILD2, Paris, Île-de-France Region, France